RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+1.96%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$7.51B
AUM Growth
+$7.51B
(-13%)
Cap. Flow
+$76.9M
Cap. Flow
% of AUM
1.02%
Top 10 Holdings %
Top 10 Hldgs %
57.63%
Holding
98
New
17
Increased
9
Reduced
16
Closed
9
Top Buys
| 1 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$160M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$111M |
| 3 |
Arcellx
ACLX
|
$71.8M |
| 4 |
Janux Therapeutics
JANX
|
$64.2M |
| 5 |
Ascendis Pharma
ASND
|
$55.4M |
Top Sells
| 1 |
Biogen
BIIB
|
$230M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$151M |
| 3 |
Evolent Health
EVH
|
$55.5M |
| 4 |
CG Oncology
CGON
|
$52.7M |
| 5 |
Recursion Pharmaceuticals
RXRX
|
$51.8M |
Sector Composition
| 1 | Healthcare | 98.36% |
| 2 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Mineralys Therapeutics
MLYS
$1.94B
| $59.7M | 0.79% |
4,850,984
| – | – |
|
27
Praxis Precision Medicines
PRAX
$980M
| $58.6M | 0.78% |
761,955
| – | – |
|
|
CLYM
28
Climb Bio, Inc. Common Stock
CLYM
$165M
| $56.6M | 0.75% |
31,419,267
| – | – |
|
|
29
Recursion Pharmaceuticals
RXRX
$2.02B
| $52.2M | 0.7% |
7,725,096
-7,659,519
| -50% | -$51.8M |
|
30
Tourmaline Bio
TRML
$645M
| $51.5M | 0.69% |
2,538,925
| – | – |
|
31
Acrivon Therapeutics
ACRV
$42.2M
| $50.2M | 0.67% |
8,340,508
| – | – |
|
32
Fulcrum Therapeutics
FULC
$353M
| $48.1M | 0.64% |
10,229,099
| – | – |
|
33
10x Genomics
TXG
$1.66B
| $47.1M | 0.63% |
+3,279,401
| New | +$47.1M |
|
34
GH Research
GHRS
$870M
| $46.8M | 0.62% |
6,686,689
| – | – |
|
35
Astria Therapeutics
ATXS
$394M
| $45.6M | 0.61% |
5,105,213
| – | – |
|
36
Vor Biopharma
VOR
$253M
| $44M | 0.59% |
39,646,039
+16,897,159
| +74% | +$18.8M |
|
37
Structure Therapeutics
GPCR
$1.14B
| $41.2M | 0.55% |
1,517,418
-379,354
| -20% | -$10.3M |
|
38
Dianthus Therapeutics
DNTH
$781M
| $40.7M | 0.54% |
1,866,400
-466,600
| -20% | -$10.2M |
|
39
PepGen
PEPG
$39M
| $40.5M | 0.54% |
10,689,545
| – | – |
|
|
40
Evolent Health
EVH
$1.11B
| $40.2M | 0.54% |
3,577,197
-4,937,665
| -58% | -$55.5M |
|
41
Kura Oncology
KURA
$732M
| $38.8M | 0.52% |
+4,451,041
| New | +$38.8M |
|
42
IDEAYA Biosciences
IDYA
$2.26B
| $34.6M | 0.46% |
1,347,252
| – | – |
|
43
Zai Lab
ZLAB
$3.48B
| $33.9M | 0.45% |
+1,295,040
| New | +$33.9M |
|
|
CMRX
44
DELISTED
Chimerix, Inc.
CMRX
| $30.6M | 0.41% |
8,800,000
| – | – |
|
45
Cidara Therapeutics
CDTX
$1.61B
| $29.4M | 0.39% |
1,092,796
+389,716
| +55% | +$10.5M |
|
|
MBX
46
MBX Biosciences, Inc. Common Stock
MBX
$484M
| $27.9M | 0.37% |
1,511,334
| – | – |
|
47
Nkarta
NKTX
$149M
| $26.9M | 0.36% |
10,805,129
| – | – |
|
48
Acumen Pharmaceuticals
ABOS
$84.2M
| $25.7M | 0.34% |
14,932,063
| – | – |
|
49
4D Molecular Therapeutics
FDMT
$302M
| $25.4M | 0.34% |
4,563,211
-535,000
| -10% | -$2.98M |
|
50
Nurix Therapeutics
NRIX
$723M
| $25.1M | 0.33% |
+1,333,333
| New | +$25.1M |
|